Julie Rousseau

Julie Rousseau is currently the Associate Director of Translational Biology at Alpha-9 Oncology. Prior to this, Julie held positions at BC Cancer, Ecole nationale vétérinaire de Nantes, ESAV Institut Bonaparte, Inserm, and Pfizer. Julie's educational background includes a PhD in Molecular and Cellular Aspects of Biology from Nantes Université, as well as a Master's degree in Cellular Biology, Physiology, Biotechnologies, and Therapeutic Research. Throughout their career, Julie has focused on various research projects in molecular oncology, radiolabeled antibodies for therapy and imaging, bone marrow toxicity in internal radiotherapy, and the development of RNA interference molecules as therapeutic agents for rare bone diseases.